ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v22i2.2869ppharm-2599Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWЭкспериментальное моделирование в офтальмологии как основа разработки новых путей профилактики слепоты и слабовидения у недоношенных детей: обзор литературыExperimental Simulation in Ophthalmology as a Basis for the Development of New Ways to Prevent Blindness and Low Vision in Premature Infants: Literature Reviewhttps://orcid.org/0000-0002-4857-0374КатаргинаЛ. А.KatarginaLyudmila A.

Катаргина Людмила Анатольевна - д.м.н., профессор.

Москва

Lyudmila A. Katargina - MD, PhD, Professor.

Moscow

katargina@igb.ruhttps://orcid.org/0000-0001-8032-4248ПавленкоТ. А.PavlenkoTatiana A.

Павленко Татьяна Аркадьевна - к.м.н.

Москва

Tatyana А. Pavlenko, MD, PhD.

Moscow

tanya1975_@inbox.ruhttps://orcid.org/0000-0002-1799-5038БезносО. В.BeznosOlga V.

Безнос Ольга Валерьевна

Москва

Olga V. Beznos - MD.

Moscow

olval2011@mail.ruhttps://orcid.org/0000-0002-3151-6910ОсиповаН. А.OsipovaNatalya A.

Осипова Наталья Анатольевна, кандидат медицинских наук, старший научный сотрудник отдела патологии глаз у детей.

105062, Москва, ул. Садовая-Черногрязская, д. 14/19, тел.: +7 (495) 625-87-73

Natalya A. Osipova - MD, PhD.

14/19, Sadovaya Chernogryazskaya Str., Moscow, 105062

https://orcid.org/0000-0003-2103-1570ПановаА. Ю.PanovaAnna Yu.

Панова Анна Юрьевна - к.м.н.

Москва

Anna Yu. Panova - MD, PhD.

Moscow

annie_panova18@mail.ruНациональный медицинский исследовательский центр глазных болезней им. ГельмгольцаРоссияNational Medical Research Center for Eye Diseases named after HelmholtzRussian Federation202523052025222141146Copyright © Катаргина Л.А., Павленко Т.А., Безнос О.В., Осипова Н.А., Панова А.Ю., 20252025Катаргина Л.А., Павленко Т.А., Безнос О.В., Осипова Н.А., Панова А.Ю.Katargina L.A., Pavlenko T.A., Beznos O.V., Osipova N.A., Panova A.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2599

Обзор литературы содержит обобщение результатов многолетнего экспериментального исследования патогенеза ретинопатии недоношенных на крысиной модели, проводимого в ФГБУ «НМИЦ ГБ им. Гельмгольца» Минздрава России, а также данные зарубежных авторов, являющиеся основой поиска путей медикаментозной профилактики развития данного заболевания.

The literature review summarizes the results of a long-term experimental study of the pathogenesis of retinopathy of prematurity in a rat model conducted at the National Medical Research Center for Eye Diseases named after Helmholtz, as well as data from foreign authors who are the basis for finding ways to prevent the development of this disease with medication.

ретинопатия недоношенныхпрофилактикаслепотаслабовидениеэкспериментальное исследованиеretinopathy of prematuritypreventive measuresblindnesslow visionexperimental simulationОтсутствуетNot specifiedReferencesQuinn G. Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic. Eye Brain. 2016;8:31–36. doi: https://doi.org/10.2147/EB.S94436Quinn G. Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic. Eye Brain. 2016;8:31–36. doi: https://doi.org/10.2147/EB.S94436Dammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023;65(5):625–631. doi: https://doi.org/10.1111/dmcn.15468Dammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023;65(5):625–631. doi: https://doi.org/10.1111/dmcn.15468Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38(7):397–432. doi: https://doi.org/10.1136/bjo.38.7.397Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38(7):397–432. doi: https://doi.org/10.1136/bjo.38.7.397Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29(6):500– 519. doi: https://doi.org/10.1016/j.preteyeres.2010.05.003Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29(6):500– 519. doi: https://doi.org/10.1016/j.preteyeres.2010.05.003Катаргина Л.А., Осипова Н.А. Основные принципы экспериментального моделирования ретинопатии недоношенных на животных // Российская педиатрическая офтальмология. — 2014. — Т. 7. — № 1. — С. 56–60. — doi: https://doi.org/10.17816/rpoj37602Katargina LA, Osipova NA. The basic strategy of development an animal model of retinopathy of prematurity. Rossiyskaya pediatricheskaya oftal’mologiya = Russian Pediatric Ophthalmology. 2014;7(1):56–60. (In Russ). doi: https://doi.org/10.17816/rpoj37602]Катаргина Л.А., Чеснокова Н.Б., Безнос О.В. и др. Экспериментальное исследование патогенеза ретинопатии недоношенных как перспективное направление поиска новых медикаментозных подходов к ее профилактике и лечению // Российский офтальмологический журнал. — 2016. — Т. 9. — № 1. — С. 68–73. — doi: https://doi.org/10.21516/2072-0076-2016-9-1-68-72Katargina LA, Chesnokova NB, Beznos OV, et al. An experimental Study of the Pathogenesis of Retinopathy of Prematurity as a Promising Direction of Search for New Medicinal Approaches to its Prevention and Treatment. Russian Ophthalmological Journal. 2016;9(1):68–72. (In Russ). doi: https://doi.org/10.21516/2072-0076-2016-9-1-68-72]Катаргина Л.А., Хорошилова-Маслова И.П., Майбогин А.М. и др. Патоморфологические особенности развития экспериментальной ретинопатии недоношенных // Международный журнал прикладных и фундаментальных исследований. — 2017. — Т. 3. — № 2. — С. 190–194. — doi: https://doi.org/10.17513/mjpfi.11424Katargina LA, Khoroshilova-Maslova IP, Maybogin MA, et al. Pathomorphological features of the development of experimental retinopathy of prematurity. International Journal of Applied and Fundamental Research. 2017;3(2):190–194. (In Russ). doi: https://doi.org/10.17513/mjpfi.11424]Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011;23(2):173–178. doi: https://doi.org/10.1097/MOP.0b013e3283423f35Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011;23(2):173–178. doi: https://doi.org/10.1097/MOP.0b013e3283423f35Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(Suppl. А):140–144. doi: https://doi.org/10.1016/j.ghir.2004.03.030Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(Suppl. А):140–144. doi: https://doi.org/10.1016/j.ghir.2004.03.030Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515–2526. doi: https://doi.org/10.1056/NEJMra1208129Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515–2526. doi: https://doi.org/10.1056/NEJMra1208129Катаргина Л.А., Денисова Е.В., Осипова Н.А., Панова А.Ю. Роль моноаминов в регуляции ангиогенеза и перспективы их применения при ретинопатии недоношенных // Российская педиатрическая офтальмология. — 2018. — Т. 13. — № 2. — С. 76–80. — doi: https://doi.org/10.18821/1993-1859-2018-13-2-76-80Katargina LA, Denisova EV, Osipova NA, Panova AYu. The role of monoamines in regulation of angiogenesis and prospects of their application in retinopathy of prematurity. Rossiyskaya pediatricheskaya oftal’mologiya = Russian pediatric ophthalmology. 2018;13(2):76–80. (In Russ). doi: https://doi.org/10.18821/1993-1859-2018-13-2-76-80Chakroborty D, Sarkar C, Yu H, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108(51):20730–20735. doi: https://doi.org/10.1073/pnas.1108696108Chakroborty D, Sarkar C, Yu H, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108(51):20730–20735. doi: https://doi.org/10.1073/pnas.1108696108Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010;6(12):1863–1881. doi: https://doi.org/10.2217/fon.10.142Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010;6(12):1863–1881. doi: https://doi.org/10.2217/fon.10.142Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost. 2005;3(8):1835–1842. doi: https://doi.org/10.1111/j.15387836.2005.01361.xDvorak HF. Angiogenesis: update 2005. J Thromb Haemost. 2005;3(8):1835–1842. doi: https://doi.org/10.1111/j.15387836.2005.01361.xDal Monte M, Cammalleri M, Mattei E, et al. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2015;56(1):59–73. doi: https://doi.org/10.1167/iovs.14-15263Dal Monte M, Cammalleri M, Mattei E, et al. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2015;56(1):59–73. doi: https://doi.org/10.1167/iovs.14-15263Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab Invest. 2002;82(6):747– 756. doi: https://doi.org/10.1097/01.lab.0000017372.76297.ebTamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab Invest. 2002;82(6):747– 756. doi: https://doi.org/10.1097/01.lab.0000017372.76297.ebWilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond). 2013;124(10):597–615. doi: https://doi.org/10.1042/CS20120212Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond). 2013;124(10):597–615. doi: https://doi.org/10.1042/CS20120212Ola MS, Alhomida AS, Ferrario CM, Ahmad S. Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) Axis in the Pathogenesis of Diabetic Retinopathy. Curr Med Chem. 2017;24(28):3104–3114. doi: https://doi.org/10.2174/0929867324666170407141955Ola MS, Alhomida AS, Ferrario CM, Ahmad S. Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) Axis in the Pathogenesis of Diabetic Retinopathy. Curr Med Chem. 2017;24(28):3104–3114. doi: https://doi.org/10.2174/0929867324666170407141955Катаргина Л.А., Хорошилова-Маслова И.П., Бондаренко Н.С. и др. Ангиогенные свойства катехоламинов в аспекте патогенеза ретинопатии недоношенных // Российский офтальмологический журнал. — 2018. — Т. 11. — № 4. — С. 49–55. — doi: https://doi.org/10.21516/2072-0076-2018-11-4-49-54Katargina LA, Khoroshilova-Maslova IP, Bondarenko NS, et al. Angiogenic properties of catecholamines from the viewpoint of the pathogenesis of retinopathy of prematurity. Russian Ophthalmological Journal. 2018;11(4):49–54. (In Russ). doi: https://doi.org/10.21516/2072-0076-2018-11-4-49-54]Катаргина Л.А., Осипова Н.А., Панова А.Ю. и др. Роль катехоламинов в развитии патологической неоваскуляризации сетчатки на экспериментальной модели ретинопатии недоношенных у крыс // Доклады Академии наук. — 2019. — Т. 489. — № 3. — С. 313–317. — doi: https://doi.org/10.1134/S160767291906005XKatargina LA, Osipova NA, Panova AYu, et al. The role of catecholamines in the development of pathological neovascularization of the retina in an experimental model of retinopathy of prematurity in rats. Proceedings of the Academy of Sciences. 2019;489(3):313–317. (In Russ). doi: https://doi.org/10.1134/S160767291906005XКатаргина Л.А., Осипова Н.А., Панова А.Ю. и др. Оценка прогностической значимости системного уровня моноаминов в развитии ретинопатии недоношенных в эксперименте // Современные технологии в медицине. — 2021. — Т. 13. — № 3. — С. 41–46. — doi: https://doi.org/10.17691/stm2021.13.3.05Katargina LА, Osipova NА, Panova АY, et al. Prognostic value estimation of monoamines systemic level in retinopathy of prematurity in experiment. Sovremennye tehnologii v medicine. 2021;13(3):41–46. (In Russ). doi: https://doi.org/10.17691/stm2021.13.3.05Катаргина Л.А., Чеснокова Н.Б., Безнос О.В. и др. Ангиотензин-II как пусковой фактор развития ретинопатии недоношенных // Офтальмология. — 2020. — Т. 17. — № 4. — С. 746–751. — doi: https://doi.org/10.18008/1816-5095-2020-4-746-751Katargina LA, Chesnokova NB, Beznos OV, et al. Angiotensin-II as a Trigger Factor in the Development of Retinopathy of Prematurity. Ophthalmology in Russia. 2020;17(4):746–751. (In Russ). doi: https://doi.org/10.18008/1816-5095-2020-4-746-751Катаргина Л.А., Чеснокова Н.Б., Павленко Т.А. и др. Эналаприлат как новое средство профилактики развития ретинопатии недоношенных // Биомедицинская химия. — 2023. — Т. 69. — № 2. — С. 97–103. — doi: https://doi.org/10.18097/PBMC20236902097Katargina LA, Chesnokova NB, Pavlenko TA, et al. Enalaprilat as a new means of preventing the development of retinopathy of prematurity. Biomeditsinskaya Khimiya. 2023;69(2):97–103 (In Russ). doi: https://doi.org/10.18097/PBMC20236902097Dal Monte M, Martini D, Latina V, et al. Beta-adrenoreceptor (b-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53(4):2181–2192. doi: https://doi.org/10.1167/iovs.11-9408Dal Monte M, Martini D, Latina V, et al. Beta-adrenoreceptor (b-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53(4):2181–2192. doi: https://doi.org/10.1167/iovs.11-9408Ricci B, Ricci F, Maggiano N. Oxygen-induced retinopathy in the newborn rat: morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica. 2000;214(2):136–139. doi: https://doi.org/10.1159/000027483Ricci B, Ricci F, Maggiano N. Oxygen-induced retinopathy in the newborn rat: morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica. 2000;214(2):136–139. doi: https://doi.org/10.1159/000027483Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3(3):CD011893. doi: https://doi.org/10.1002/14651858.CD011893Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3(3):CD011893. doi: https://doi.org/10.1002/14651858.CD011893Stritzke A, Kabra N, Kaur S, et al. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and metaanalysis. J Perinatol. 2019;39(12):1584–1594. doi: https://doi.org/10.1038/s41372-019-0503-xStritzke A, Kabra N, Kaur S, et al. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and metaanalysis. J Perinatol. 2019;39(12):1584–1594. doi: https://doi.org/10.1038/s41372-019-0503-xKong HB, Zheng GY, He BM, et al. Clinical efficacy and safety of propranolol in the prevention and treatment of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9:631673. doi: https://doi.org/10.3389/fped.2021.631673Kong HB, Zheng GY, He BM, et al. Clinical efficacy and safety of propranolol in the prevention and treatment of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9:631673. doi: https://doi.org/10.3389/fped.2021.631673Shafique MA, Haseeb A, Uddin MMN, et al. Effectiveness of propranolol in preventing severe retinopathy of prematurity: a comprehensive systematic review and meta-analysis. Am J Ophthalmol. 2023;259:141–50. doi: https://doi.org/10.1016/j.ajo.2023.11.012Shafique MA, Haseeb A, Uddin MMN, et al. Effectiveness of propranolol in preventing severe retinopathy of prematurity: a comprehensive systematic review and meta-analysis. Am J Ophthalmol. 2023;259:141–50. doi: https://doi.org/10.1016/j.ajo.2023.11.012Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570–1577.e6. doi: https://doi.org/10.1016/j.jpeds.2013.07.049Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570–1577.e6. doi: https://doi.org/10.1016/j.jpeds.2013.07.049Filippi L, Cavallaro G, Bagnoli P, et al. Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. Pediatr Res. 2017;81(2):307–314. doi: https://doi.org/10.1038/pr.2016.230Filippi L, Cavallaro G, Bagnoli P, et al. Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. Pediatr Res. 2017;81(2):307–314. doi: https://doi.org/10.1038/pr.2016.230Filippi L, Cavallaro G, Berti E, et al. Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr. 2019;7:180. doi: https://doi.org/10.3389/fped.2019.00180Filippi L, Cavallaro G, Berti E, et al. Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr. 2019;7:180. doi: https://doi.org/10.3389/fped.2019.00180

The authors declare that there are no conflicts of interest present.